No Data
No Data
Saito Biotech (300583.SZ): Jinsaifu Biotech is mainly engaged in standardized cultivation of Chinese herbal medicines such as saffron and carbon-based chaihu, not involving longevity medicine
Gelonghui, May 23 | Saito Biotech (300583.SZ) said on the investor interactive platform that Runxin Thermal Power mainly provides steam heat to the industrial park where the company is located. Rongjun New Materials plans to supply some accessories for the company, and production and operation have not yet started. Jinsaifu Biotech is a company participating in the company. It is mainly engaged in standardized cultivation of Chinese herbal medicines such as saffron and carbon-based chaihu. It does not involve longevity medicine, and the company does not participate in specific operations. All of the company's business layout and expansion revolves around the company's industrial upgrading strategy to achieve the integrated development of “intermediates - high-end respiratory APIs - preparations”.
Saito Biotech (300583.SZ): The company is not involved in cellular immunotherapy technology
Gelonghui, May 10 | Saito Biotech (300583.SZ) is a good vanguard of investors. The company's main products are produced using genetic engineering technology and synthetic biological methods. Compared with traditional chemical production methods, the technology currently used by the company has the advantage of “two high, two low and one stable”. The company is not currently involved in cellular immunotherapy technology. Silver Valley Pharmaceutical, which is in the process of being acquired, is carrying out the opening and promotion of the new drug phenylcycloquine ammonium bromide nasal spray according to the plan.
Saito Biotech (300583.SZ): Using synthetic biological methods to produce the five major parent nuclear products of steroidal raw materials such as androstenedione, androstenedione, 9-hydroxyandrostenedione, and dialcohol
Gelonghui, May 8 | Saito Biotech (300583.SZ) said on the investor interactive platform that the company uses synthetic biological methods to produce five major parent core products with steroidal ingredients such as androstenedione, androstenedione, 9-hydroxyandrostenedione, and dialcohol to develop glucocorticoids, sex hormones, progesterone, and anabolic steroid drugs.
Shandong Sito Bio-technology Gets European Suitability Certification for Rhinitis Nasal Spray
The European Medicines Quality Administration granted Shandong Sito Bio-technology (SHE:300583) a certificate of suitability for its fluticasone propionate nasal spray, according to a Wednesday filing
Saito Biotech (300583.SZ): Net profit increased 8.67% year-on-year in 2023, plans to pay 10 to 4.5 yuan
On April 28, Gelonghui | Saito Biotech (300583.SZ) released its 2023 annual report. The company's revenue during the reporting period was 1.28 billion yuan, a decrease of 2.46% over the previous year. Net profit attributable to shareholders of listed companies was 45.604 million yuan, an increase of 8.67% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was RMB 24.529 million, a decrease of 32.70% over the previous year. Basic earnings per share were $0.25. It is proposed to distribute a cash dividend of 4.5 yuan (tax included) for every 10 shares to all shareholders.
Shandong Sito Bio-technology Co., Ltd.'s (SZSE:300583) 30% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
Shandong Sito Bio-technology Co., Ltd. (SZSE:300583) shareholders that were waiting for something to happen have been dealt a blow with a 30% share price drop in the last month. The drop over the l
No Data